KSQ THERAPEUTICS

KSQ is deploying its CRISPRomics platform, which pinpoints therapeutic nodes that directly correlate genomic function to disease, for new drug development... Genome-scale understanding of biology is enabling breakthrough medicines. We are a clinical-stage company using our CRISPRomics® discovery platform to systematically decode the genome to identify optimal gene targets for oncology and autoimmune disease. And we're using our drug development capabilities, including our first-in-class USP1 inhibitor KSQ-4279 and our eTIL® autologous cell therapy platform, to rewire human biology with the potential to cure diseases.This genome-wide depth and cell-type breadth unlocks an unparalleled pipeline opportunity with significant curative potential for a wide range of human diseases... KSQ-4279 is a first-in-class small molecule inhibitor of USP1 and is currently in a Phase 1 clinical trial in patients with advanced solid tumors, both as a monotherapy and in combination. Because of its..

Also known as: KSQ Therapeutics, Inc.

Primary location: Lexington United States